The First Hospital of China Medical University
Welcome,         Profile    Billing    Logout  
 976 Trials 
2645 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Han, Yaling
NCT03287167: Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease

Recruiting
4
1720
RoW
1 month DAPT, 6 months DAPT
Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Disease, Drug Eluting Stent, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
07/21
07/23
DESSOLVE-C, NCT02448524: Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)

Active, not recruiting
3
428
RoW
MiStent, TIVOLI
Micell Technologies, Hefei Life Science Medical Instruments Co. Ltd., Giant Med-Pharma Services Inc., CCRF Consulting Co., Ltd.
Coronary Heart Disease
11/18
11/22
NCT04781114: The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

Completed
3
806
RoW
JS002, Placebo
Shanghai Junshi Bioscience Co., Ltd.
Hyperlipemia
05/22
01/23
VCP1-III-01, NCT06577519: Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Recruiting
3
1000
RoW
Vicagrel, Clopidogrel
Jiangsu vcare pharmaceutical technology co., LTD
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
12/26
12/26
PADN-HF-PH, NCT05824923: A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure

Recruiting
3
264
RoW
Pulmonary arterial denervation, PADN, Guideline-directed medical therapy (GDMT) for heart failure, GDMT medication for heart failure
Pulnovo Medical (Wuxi) Co., Ltd., The General Hospital of Northern Theater Command, The First Affiliated Hospital with Nanjing Medical University, First Hospital of Tsinghua University, Cangzhou Central Hospital, Fuwai Central China Cardiovascular Hospital, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Guangzhou Medical University, First Affiliated Hospital of Harbin Medical University, Tongji Hospital, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University, Shanxi Cardiovascular Hospital, RenJi Hospital, Shanghai 10th People's Hospital, Beijing Anzhen Hospital, West China Hospital, Sichuan Academy of Medical Sciences, The First Affiliated Hospital of Soochow University, TEDA International Cardiovascular Hospital, Tianjin Medical University General Hospital, Renmin Hospital of Wuhan University, Zhongnan Hospital of Wuhan University, First Affiliated Hospital Xi'an Jiaotong University, Xiamen Cardiovascular Hospital, Xiamen University, Zhejiang University, Shengjing Hospital, First Affiliated Hospital of Fujian Medical University, First Affiliated Hospital of Wenzhou Medical University, Gansu Provincial Hospital, Yanan Hospital of Kunming City, First Affiliated Hospital of Chongqing Medical University, Huaihe Hospital of Henan University, Zhengzhou Cardiovascular Hospital, Wuhan Union Hospital, China, The First Affiliated Hospital of Nanchang University, Hunan Provincial People's Hospital, Tianjin Medical University Second Hospital, First Affiliated Hospital, Sun Yat-Sen University, The First Hospital of Jilin University
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases, Cardiovascular Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
08/25
02/27
NCT06339021: OCT or Angiography Guided De-escalation of DAPT

Not yet recruiting
1
80
RoW
OCT-guided PCI, Conventional angiography-based PCI, DAPT de-escalation, default DAPT regimen
Shenyang Northern Hospital
Optical Coherence Tomography, Dual Antiplatelet Therapy, Antiplatelet De-escalation, Neointimal Coverage, ST Elevation Myocardial Infarction
12/26
12/26
NCT03040934: Firehawk™ Coronary Stent System in the Treatment of Coronary Chronic Total Occlusion Lesion(s)

Active, not recruiting
N/A
196
RoW
Firehawk sirolimus target eluting coronary stent system, Firehawk™, XIENCE Everolimus-Eluting Coronary Stent System, XIENCE EES
Shanghai MicroPort Medical (Group) Co., Ltd.
Drug-Eluting Stents, Percutaneous Coronary Intervention, Tomography, Optical Coherence
09/19
10/23
NCT04569669: The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis

Not yet recruiting
N/A
325
RoW
FFR and FFRCT
CCRF Inc., Beijing, China, Shengshi Technology, Co., Ltd, Hangzhou, China
Coronary Stenosis
10/21
03/22
SIBLINT ISR, NCT04240444: Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis

Completed
N/A
260
RoW
drug-coated balloon Catheter
B. Braun Medical International Trading Company Ltd., CCRF Inc., Beijing, China
Coronary Artery Disease, In Stent Restenosis
07/22
08/22
BEYOND-II, NCT03820622: The Safety and Efficacy of DIOR Balloon in Coronary Bifurcation Lesions

Not yet recruiting
N/A
220
RoW
Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR), Paclitaxel-Eluting Balloon (Bingo)
CCRF Inc., Beijing, China
Percutaneous Coronary Intervention
05/22
10/22
BRIGHT-4, NCT03822975: Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI

Active, not recruiting
N/A
6016
RoW
Bivalirudin, unfractionated Heparin
Shenyang Northern Hospital
ST Elevation Myocardial Infarction
05/22
05/23
NCT05040074: SQ-Kyrin TMVr FIM Study

Recruiting
N/A
20
RoW
SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System
Shanghai Shenqi Medical Technology Co., Ltd
Mitral Regurgitation
10/22
10/26
NCT05375110: NoYA RAISE Trial II (Radiofrequency Ablation-Based Interatrial Shunt for Heart Failure)

Recruiting
N/A
120
RoW
NoYAâ„¢ Radiofrequency Interatrial Shunt System
Hangzhou NOYA MedTech Co. Ltm.
Heart Failure
12/22
12/23
NCT05015712: Effects of MICT on Cardiopulmonary Function in Patients After TAVI

Recruiting
N/A
66
RoW
moderate intensity continuous training
Han Yaling, MD
Valve Disease, Aortic, Cardiac Rehabilitation
06/23
06/23
NCT05988450: Safety and Effectiveness Study of SQ-Kyrin TMVr System for Functional Mitral Regurgitation

Active, not recruiting
N/A
125
RoW
SQ-Kyrin Transcatheter Mitral Valve Repair System
Shanghai Shenqi Medical Technology Co., Ltd
Functional Mitral Regurgitation
12/23
12/27
OPT-GUIDNACE, NCT06216821: OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time

Not yet recruiting
N/A
3490
RoW
standard DAPT, OPT-CAD score guided DAPT de-escalation
Shenyang Northern Hospital
Acute Coronary Syndrome
12/25
12/25
COCAD, NCT06216847: Clinical Outcomes of Patients With Coronary Artery Disease

Not yet recruiting
N/A
10000
RoW
Shenyang Northern Hospital
Coronary Heart Disease (CHD)
10/26
10/30
NCT06357026: Phitys I™ Percutaneous Left Ventricular Assist System Study

Not yet recruiting
N/A
344
RoW
Percutaneous Ventricular Assist System(Phigine Medical), intra-aortic balloon pump (IABP)
Shanghai NewMed Medical Co., Ltd., Shanghai Phigine Medical Technology Co., Ltd.
Coronary Artery Disease
05/25
04/26
NCT05864456: Prizvalve Pro™ Transcatheter Aortic Valve Replacement Study

Recruiting
N/A
73
RoW
Prizvalve Pro™ transcatheter aortic valve system
Shanghai NewMed Medical Co., Ltd., The General Hospital of Northern Theater Command, West China Hospital
Aortic Valve Stenosis
06/24
05/28
NCT06491953: SGLT2-inhibitors on PC-AKI

Recruiting
N/A
3600
RoW
SGLT-2 inhibitors
Shenyang Northern Hospital
Impact of SGLT2-inhibitors on PC-AKI in ACS Patients Receiving Invasive Strategy
12/24
12/24
NCT06101888: Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR)

Recruiting
N/A
116
RoW
TaurusTrio™ Heart Valve System
Peijia Medical Technology (Suzhou) Co., Ltd.
Aortic Regurgitation
07/24
07/29
DragonFire-02, NCT06368037: Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy

Not yet recruiting
N/A
10
RoW
DragonFire Transcatheter Myocardial Radiofrequency Ablation System
Hangzhou Valgen Medtech Co., Ltd
Obstructive Hypertrophic Cardiomyopathy
06/25
06/26
NCT06639321: Phimume® Percutaneous Left Ventricular Assist System Study

Not yet recruiting
N/A
250
RoW
Percutaneous Ventricular Assist System, extracorporeal membrane oxygenation (ECMO)
Shanghai NewMed Medical Co., Ltd., Shanghai Phigine Medical Technology Co., Ltd.
Coronary Artery Disease
11/25
10/26
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus

Recruiting
N/A
184
RoW
Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter
Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Coronary Artery Disease, Intravascular Lithotripsy
12/24
09/25
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System

Not yet recruiting
N/A
2150
RoW
Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy
Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Heart Disease
01/26
01/28
CRUISE-CTO, NCT04944615: To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease.

Recruiting
N/A
1448
RoW
The guidewire successfully passed the CTO lesion, Load dose administration
CCRF Inc., Beijing, China, BSC International Medical Trading (Shanghai) Co., Ltd.
Chronic Total Occlusion of Coronary Artery
10/31
10/31
CHIP-RETENTION, NCT04987268: CHIP and Residual Cardiovascular Event Tendency After Smoking Cessation

Not yet recruiting
N/A
1029
RoW
clonal hematopoiesis of indeterminate potential
Shenyang Northern Hospital
ACS, Clonal Hematopoiesis of Indeterminate Potential, Smoking Cessation
08/23
08/24
Li, Yan
NCT04035824: Gastrodia and Uncaria Recipe in Treating Stage-one Hypertension: an Evidence-based Optimization Study

Completed
4
605
RoW
Gastrodia and Uncaria granule, Placebo of Gastrodia and Uncaria granule
Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hypertension
04/24
04/24
NCT05089448: Morning Versus Bedtime Dosing of Antihypertensive Medication

Recruiting
4
300
RoW
Alisartan, Amlodipine besylate
Yan Li
Hypertension, Blood Pressure, Drug Use
06/26
09/26
NCT03825692: International Clinical Study of Zhizhu Kuanzhong Capsule

Recruiting
4
480
RoW
Zhizhu Kuanzhong Capsule, ZZKZ capsule, Zhizhu Kuanzhong Placebo Capsule, placebo
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Functional Dyspepsia, Postprandial Distress Syndrome
12/23
12/23
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Checkmark Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
Checkmark Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Completed
3
1177
Europe, Canada, Japan, US, RoW
Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC
Eli Lilly and Company
Ulcerative Colitis
11/21
12/24
NCT04078568: Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease

Active, not recruiting
3
3208
RoW
IVIG, Intravenous Immunoglobulins, Human, Aspirin, Acetylsalicylic acid, Prednisolone, STEROLONE
Children's Hospital of Fudan University, Jiangxi Province Children's Hospital, First People's Hospital of Hangzhou, Shengjing Hospital, The First Hospital of Jilin University, Chengdu Women's and Children's Central Hospital, Children's Hospital of Chongqing Medical University, Inner Mongolia People's Hospital, Sichuan Provincial People's Hospital, Wuhan Union Hospital, China, Third Affiliated Hospital of Zhengzhou University, Children's Hospital of Soochow University, Yuying Children's Hospital of Wenzhou Medical University, Beijing Children's Hospital, Qilu Hospital of Shandong University
Kawasaki Disease
12/24
12/25
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Active, not recruiting
3
274
RoW
BPI-16350, placebo, Fulvestrant
Betta Pharmaceuticals Co., Ltd.
Breast Cancer
12/23
07/25
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration

Active, not recruiting
3
488
RoW
TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis
TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Neovascular Age-related Macular Degeneration
09/24
02/25
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
928
Europe, Canada, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Diabetes, Type 2 Diabetes
04/24
04/24
TRAPP, NCT05811676: Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women with Placenta Previa

Recruiting
3
1680
RoW
Tranexamic acid, 0.9% sodium chloride
Guangzhou Medical University, Dongguan Maternal and Child Health Care Hospital, Foshan Women and Children Hospital, BoAi Hospital of Zhongshan, Women and Children's Hospital of Chongqing Medical University, Tianjin Central Hospital of Gynecology Obstetrics, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Urumqi Maternal and Child Health Care Hospital, Zhuhai Women and Children's Hospital, The First Affiliated Hospital of Zhengzhou University, Hunan Provincial Maternal and Child Health Care Hospital, Dalian women and children's medical group, Nanfang Hospital, Southern Medical University, Huadu District People's Hospital of Guangzhou, Northwest Women's and Children's Hospital, Xi'an, Shaanxi, First Affiliated Hospital, Sun Yat-Sen University, Shenzhen Maternity & Child Healthcare Hospital, Shenzhen Baoan Women's and Children's Hospital, Dongguan People's Hospital, First Affiliated Hospital of Xinjiang Medical University, Tongji Hospital, Peking Union Medical College, Peking University First Hospital, The First Affiliated Hospital of Guangzhou Medical University, Second Affiliated Hospital of Guangzhou Medical University, Fifth Affiliated Hospital of Guangzhou Medical University, Shijiazhuang Obstetrics and Gynecology Hospital
Hemorrhage, Postpartum, Placenta Previa
02/25
04/25
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Recruiting
3
218
RoW
ICP-022, Chlorambucil, Rituximab
Beijing InnoCare Pharma Tech Co., Ltd.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/24
06/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT06083623: A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants

Not yet recruiting
2b
2250
RoW
TNM001, placebo
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Respiratory Syncytial Virus Infections
05/26
08/26
NCT04405154: A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer

Not yet recruiting
2
32
NA
Camrelizumab, SHR-1210, Cisplatin, Platinol, IMRT or VMAT
West China Hospital
Head and Neck Neoplasms
05/23
05/25
NCT05299697: A Study of TG103 Injection in Overweight or Obesity

Recruiting
2
195
RoW
TG103 15 mg, TG103 22.5 mg, Placebo
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Overweight or Obesity
06/23
09/23
NCT06206720: A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV

Recruiting
2
60
RoW
Deuremidevir Hydrobromide for Suspension, VV116, Placebo, VV116 placebo
Vigonvita Life Sciences
Respiratory Syncytial Virus Infection
01/25
01/25
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

Not yet recruiting
2
318
RoW
HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes
04/25
04/25
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases

Active, not recruiting
2
103
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627
Novartis Pharmaceuticals
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
07/24
07/26
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
498
Europe, RoW
SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate
Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
12/25
10/26
NCT05879055: A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Recruiting
2
60
RoW
PM8002, FOLFIRI
Biotheus Inc.
Neuroendocrine Neoplasm
01/27
01/28
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Recruiting
1/2
39
RoW
400mg of TQB3909 tablets, 600mg of TQB3909 tablets
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Mantle Cell Lymphoma
12/24
12/24
NCT06052813: A Study of BN104 in the Treatment of Acute Leukemia

Recruiting
1/2
90
RoW
BN104
BioNova Pharmaceuticals (Shanghai) LTD.
ALL, Adult, AML, Adult
06/26
06/27
NCT05056389: Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA)

Recruiting
1
20
Europe
Oxaliplatin, Intraperitoneal catheter
Oslo University Hospital
Peritoneal Metastases, Colo-rectal Cancer
03/23
06/23
NCT05480592: A Study of HS-10380 in Chinese Participants

Recruiting
1
76
RoW
HS-10380, Placebo
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Schizophrenia
06/23
07/23
NCT06594315: Assessing Brain Metabolism Using MRS With Deuterated Glucose

Active, not recruiting
N/A
80
US
Deuterated Glucose, Hydrogen gas (H2) glucose, [6,6'-2H2] glucose, Magnetic Resonance Imaging (MRI), MRI, Blood Sample, MR spectroscopy (MRS), MRS
University of California, San Francisco
Glioma
07/27
07/27
NCT06610604: Health-Related Quality of Life and Emotions in Patients with Thyroid Nodules

Recruiting
N/A
500
RoW
thermal ablation, thyroidectomy
Ming-an Yu
Thyroid Nodule
06/27
12/27
NCT05258461: An Innovative Smartphone Application for Adverse Event Management During Breast Cancer Adjuvant Chemotherapy

Not yet recruiting
N/A
108
NA
use of a smartphone app for adverse event management, conventional adverse event management
Peking Union Medical College Hospital
Breast Cancer
10/22
12/22
NCT03547856: A Registry Study on the "Action of Controlling Ambulatory Blood Pressure to Target in Ten Thousand Patients"

Recruiting
N/A
10000
RoW
Yan Li
Hypertension, Blood Pressure, Cardiovascular Diseases
09/26
12/26
ASORPWICE, NCT03521739: Association of Synchronous Four-limb blOod pRessure and Pulse Wave velocIty With Cardiovascular Events

Recruiting
N/A
100000
RoW
Chinese Academy of Medical Sciences, Fuwai Hospital
Blood Pressure, Pulse Wave Analysis, Ankle Brachial Index, Patient Outcome Assessment
12/22
12/23
CONTROL-NHT, NCT04137549: Registry Study on "Control Nocturnal Hypertension to Reach the Target "

Recruiting
N/A
4500
RoW
Shanghai Institute of Hypertension
Nocturnal Hypertension
09/26
12/26
PROMISE, NCT04135911: A Prospective Study on The"Management of Hypertension in Young and Middle-aged Subjects in Enterprises Setting"

Suspended
N/A
2000
RoW
Yan Li
Hypertension, Blood Pressure
03/26
03/26
NCT05535400: Effects of Physical-Psychological Integrative Intervention on SCI Patient: a Pilot Randomized Controlled Trial

Completed
N/A
72
RoW
Physical-Psychological Integrative Intervention, Brief online didactic education
The Hong Kong Polytechnic University
Spinal Cord Injuries, Physical Inactivity, Depression, Chronic Pain
12/22
07/23
NCT04258787: OCT in Fuchs' Dystrophy

Recruiting
N/A
60
US
Oregon Health and Science University, National Eye Institute (NEI)
Fuchs Dystrophy, Pseudophakic Bullous Keratopathy
06/26
06/26
NCT05558657: Effect of Acupressure on Constipation in Community-dwelling Spinal Cord Injury Patients: a Randomized Controlled Trial

Completed
N/A
80
RoW
Home-based, acupressure combined with nursing education, Home-based, manual light touch of the abdomen combined with nursing education
The Hong Kong Polytechnic University
Spinal Cord Injuries, Traditional Chinese Medicine
09/24
09/24
NCT05531058: The Impact of a Web-based Psychoeducation Programme With a Motivational AI Chatbot on Covid-19 Vaccine Hesitancy

Completed
N/A
168
RoW
AI-driven Vaccine Communicator, Self-learning of COVID-19 vaccine knowledge
The Hong Kong Polytechnic University
Vaccine Hesitancy, COVID-19
06/24
06/24
NCT01243931: Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

Recruiting
N/A
80
US
OCT-guided laser phototherapeutic keratectomy, Manufacturer/Name OCT Technology 510(K), Optovue/RTVue-CAM Fourier-domain K071250, Bioptigen/Bioptigen Fourier-domain K063343, Zeiss/Visante Time-domain K051789
Oregon Health and Science University, National Eye Institute (NEI)
Corneal Opacity
12/26
12/26
NCT02109471: Observational Study of Corneal Opacities in Adults

Recruiting
N/A
150
US
Oregon Health and Science University, National Eye Institute (NEI)
Corneal Opacities (Scar and Stromal Dystrophy)
12/25
12/25
NCT02026128: Optical Coherence Tomography (OCT) in Uveitis

Recruiting
N/A
75
US
Oregon Health and Science University
Uveitis
12/25
12/25
NCT06306378: The Relationship Between Social Memory Disorders and Sleep Spindles in Children With Autism Spectrum Disorder

Recruiting
N/A
60
RoW
social memory levels and spindle levels
First Affiliated Hospital Xi'an Jiaotong University, Xi'an TCM Hospital of Encephalopathy
Autism Spectrum Disorder
03/24
04/24
NCT03504800: OCT in Diagnosis of Irregular Corneas

Recruiting
N/A
445
US
Optical Coherence Tomography
Oregon Health and Science University
Keratoconus, Corneal Opacity, Corneal Dystrophy
04/25
04/26
NCT05388110: SKY Breath Intervention

Active, not recruiting
N/A
60
US
SKY Breath Intervention
University of California, San Francisco
Depression, Anxiety Disorders
04/25
12/25
OCT IOL, NCT00532051: Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography

Recruiting
N/A
690
US
OCT measurements, Manufacturer/Name OCT Technology 510(K), Optovue/RTVue-CAM Fourier-domain K071250, Bioptigen/Bioptigen Fourier-domain K063343, Zeiss/Visante Time-domain K051789
Oregon Health and Science University, National Eye Institute (NEI)
Cataract
07/26
07/26
NCT06686134: Comprehensive Clinical Evaluation Study of GLP-1RA

Recruiting
N/A
492
RoW
LI YAN
T2DM
12/25
07/26
INFINITE, NCT04328662: A Study of Ninlaro in Real World Clinical Practice in China

Active, not recruiting
N/A
482
RoW
Takeda
Multiple Myeloma, Neoplasms, Plasma Cell
09/25
09/25
TEAS/ASD, NCT06763237: Abdominal Transcutaneous Electrical Acupoint Stimulation on Children With Autism Spectrum Disorder

Not yet recruiting
N/A
42
RoW
abdominal transcutaneous electrical acupoint stimulation (abdominal TEAS), TEAS, Applied Behavior Analysis (ABA) therapy
First Affiliated Hospital Xi'an Jiaotong University, Xian Children's Hospital
Autism Spectrum Disorder, Autism in Children
01/26
01/26
NCT06839378: Flura-seq for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei

Recruiting
N/A
36
RoW
intravenously inject with 5-FU (400 mg/m2)
Beijing Tsinghua Chang Gung Hospital, Tsinghua University
Pseudomyxoma Peritonei
02/26
02/27
NCT05282095: Effect of HPV Integration on Prognosis of Young Women With CIN2 in China

Recruiting
N/A
300
RoW
Follow up
Fujian Maternity and Child Health Hospital
Cervical Intraepithelial Neoplasia, HPV Infection, Virus Integration, HSIL, High Grade Squamous Intraepithelial Lesions
12/25
05/26
NCT05881967: Molecular Mechanism Study of Uterine Sarcoma

Recruiting
N/A
300
RoW
Diagnostic biomarker
Shixuan Wang
Uterine Sarcoma
11/25
11/25
NCT04570020: Scleral Lens Fitting Using Wide-Field OCT

Recruiting
N/A
258
US
Oregon Health and Science University, National Eye Institute (NEI)
Keratoconus, Irregular; Contour of Cornea
12/25
12/26
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System

Not yet recruiting
N/A
2150
RoW
Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy
Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Heart Disease
01/26
01/28
SHAFT, NCT04574336: Scandinavian Humeral Diaphyseal Fracture Trial

Recruiting
N/A
287
Europe
Surgical treatment, Non-surgical treatment
Kolding Sygehus, Copenhagen University Hospital, Hvidovre, Zealand University Hospital, Oslo University Hospital, Helse Stavanger HF, Sahlgrenska University Hospital, Sweden, Uppsala University Hospital, Odense University Hospital, Hospital of Southern Jutland, Slagelse Hospital, Aalborg University Hospital, University Hospital, Umeå, Nordsjaellands Hospital, Holbaek Sygehus, Aarhus University Hospital, Copenhagen University Hospital, Herlev-Gentofte, University Hospital Bispebjerg and Frederiksberg, Viborg Regional Hospital, Karolinska University Hospital, Danderyd Hospital, Tampere University Hospital, Helsinki University Central Hospital
Fracture Humerus of Shaft
12/25
07/31
NCT05858944: Home Blood Pressure Intervention in the Community Trial

Recruiting
N/A
10000
RoW
Intensive Home BP control, Home BP<125/75 mmHg, Standard Home BP control, Home BP<135/85 mmHg
Shanghai Institute of Hypertension
Home Blood Pressure
12/29
06/30
MBS, NCT05205187: Gut Microbiota and Metabonomics

Recruiting
N/A
450
RoW
Healthy control specimen collection, Non-Borrmann IV patient specimen collection, Borrmann IV patient specimen collection
First Hospital of China Medical University, Liaoning Cancer Hospital & Institute, The Second Hospital of Shandong University, The General Hospital of Fushun Mining Bureau, The fourth People's Hospital of Changzhou, The First People's Hospital of Jingzhou
Stomach Neoplasms, Gut Microbiota, Metabolomics
01/24
12/25
LORMYF, NCT05424393: Real-World Study on Long-term Treatment With YISAIPU for Fujian RA Patients

Recruiting
N/A
500
RoW
YISAIPU® ( An etanercept biosimilar), a recombinant tumor necrosis factor receptor-Fc fusion protein, rhTNFR:Fc, csDMARDs
The First Affiliated Hospital of Xiamen University
Rheumatoid Arthritis
06/25
12/25
Fan, Jia
NCT05660213: Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC)

Not yet recruiting
4
600
NA
Huaier granule, Atezolizumab + Bevacizumab, Camrelizumab+Apatinib, Sintilimab+Bevacizumab
Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology
Unresectable Hepatocellular Carcinoma
09/25
01/27
NCT04720716: A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Recruiting
3
490
RoW
IBI310, Sintilimab, Sorafenib
Innovent Biologics (Suzhou) Co. Ltd.
Hepatocellular Carcinoma
12/23
12/23
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Active, not recruiting
3
648
RoW
AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Hepatocellular Carcinoma (HCC)
12/26
12/26
NCT05320692: A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

Recruiting
3
425
RoW
TACE+Camrelizumab+Apatinib mesylate, TACE
Jiangsu HengRui Medicine Co., Ltd.
Hepatocellular Carcinoma
07/26
07/26
EMERALD-2, NCT03847428 / 2018-004105-85: Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

Hourglass Jan 2022 - Dec 2023 : Acceptance of regulatory submission in China for HCC based on EMERALD-2 trial
Jan 2023 - Jun 2023: Data from EMERALD-2 trial for HCC
Active, not recruiting
3
908
Europe, Canada, Japan, US, RoW
Durvalumab, IMFINZI, Bevacizumab, AVASTIN, Placebo
AstraZeneca, AstraZeneca AB
Hepatocellular Carcinoma
05/26
05/27
AK104-306, NCT05489289: A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Not yet recruiting
3
405
RoW
AK104, placebo
Akeso
Hepatocellular Carcinoma
01/25
11/26
NCT04669496: Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors

Recruiting
2/3
178
RoW
Neoadjuvant treatment
Shanghai Zhongshan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 6th People's Hospital, Shanghai Public Health Clinical Center, RenJi Hospital, Shenzhen University General Hospital
Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy
12/25
12/26
DUBHE-H-308, NCT05976568: A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Not yet recruiting
2/3
668
RoW
QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine, Sintilimab
Qilu Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
09/27
09/27
NCT04506281: PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Recruiting
2
128
RoW
neoadjuvant treatment
Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Minhang Hospital, Fudan University, Shanghai Jinshan Hospital, Shenzhen University General Hospital
Cholangiocarcinoma, Intrahepatic
08/21
08/23
ZSAB-TOP, NCT05023109: GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC

Active, not recruiting
2
45
RoW
GP+PD-1+Tight
Shanghai Zhongshan Hospital, Jining Medical University, Cancer Hospital of Guangxi Medical University
Biliary Tract Carcinoma
01/23
12/24
NCT05190575: TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer

Completed
2
8
RoW
TST001
Shanghai Zhongshan Hospital, Transcenta Holding Limited
Biliary Tract Neoplasms
05/23
05/23
ZSAB-TransGOLP, NCT05156788: Tislelizumab(Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Active, not recruiting
2
40
RoW
PD-1+Lenvatinib+GEMOX
Shanghai Zhongshan Hospital
Biliary Tract Cancer, PD-1 Antibody, Gemox, Lenvatinib
07/23
10/25
NCT04550624: Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma

Recruiting
2
40
RoW
Pembrolizumab Injection [Keytruda], Keytruda, Lenvatinib Mesylate, Lenvima
Shanghai Jiahui International Hospital, Shanghai Zhongshan Hospital
Advanced Biliary Tract Carcinoma
12/24
12/25
SHR-A1811-212, NCT06413745: Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

Recruiting
2
65
RoW
SHR-A1811
Jiangsu HengRui Medicine Co., Ltd.
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
09/25
09/25
NCT06349980: A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

Recruiting
2
117
RoW
HLX53 (1000mg), HLX53 (2000mg), HLX10, Serplulimab, HLX04, Bevacizumab, Placebo
Shanghai Henlius Biotech
Carcinoma, Hepatocellular
02/27
02/27
NCT06620848: A Study of HRS-4642 Monotherapy or in Combination with Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.

Not yet recruiting
2
49
RoW
HRS-4642 monotherapy, HRS-4642 and adebrelimab combination therapy
Shanghai Zhongshan Hospital
Biliary Tract Cancer
12/26
06/27
FAITH, NCT06031480: Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors

Not yet recruiting
2
55
RoW
Anlotinib and TQB2450
Shanghai Zhongshan Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatocellular Carcinoma
10/25
12/25
NCT03867370: Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Terminated
1/2
40
RoW
Toripalimab (JS001 ), Toripalimab (JS001 ) Lenvatinib
Shanghai Junshi Bioscience Co., Ltd.
Hepatocellular Carcinoma
08/23
08/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Han, Yaling
NCT03287167: Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease

Recruiting
4
1720
RoW
1 month DAPT, 6 months DAPT
Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Disease, Drug Eluting Stent, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
07/21
07/23
DESSOLVE-C, NCT02448524: Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)

Active, not recruiting
3
428
RoW
MiStent, TIVOLI
Micell Technologies, Hefei Life Science Medical Instruments Co. Ltd., Giant Med-Pharma Services Inc., CCRF Consulting Co., Ltd.
Coronary Heart Disease
11/18
11/22
NCT04781114: The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

Completed
3
806
RoW
JS002, Placebo
Shanghai Junshi Bioscience Co., Ltd.
Hyperlipemia
05/22
01/23
VCP1-III-01, NCT06577519: Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Recruiting
3
1000
RoW
Vicagrel, Clopidogrel
Jiangsu vcare pharmaceutical technology co., LTD
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
12/26
12/26
PADN-HF-PH, NCT05824923: A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure

Recruiting
3
264
RoW
Pulmonary arterial denervation, PADN, Guideline-directed medical therapy (GDMT) for heart failure, GDMT medication for heart failure
Pulnovo Medical (Wuxi) Co., Ltd., The General Hospital of Northern Theater Command, The First Affiliated Hospital with Nanjing Medical University, First Hospital of Tsinghua University, Cangzhou Central Hospital, Fuwai Central China Cardiovascular Hospital, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Guangzhou Medical University, First Affiliated Hospital of Harbin Medical University, Tongji Hospital, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University, Shanxi Cardiovascular Hospital, RenJi Hospital, Shanghai 10th People's Hospital, Beijing Anzhen Hospital, West China Hospital, Sichuan Academy of Medical Sciences, The First Affiliated Hospital of Soochow University, TEDA International Cardiovascular Hospital, Tianjin Medical University General Hospital, Renmin Hospital of Wuhan University, Zhongnan Hospital of Wuhan University, First Affiliated Hospital Xi'an Jiaotong University, Xiamen Cardiovascular Hospital, Xiamen University, Zhejiang University, Shengjing Hospital, First Affiliated Hospital of Fujian Medical University, First Affiliated Hospital of Wenzhou Medical University, Gansu Provincial Hospital, Yanan Hospital of Kunming City, First Affiliated Hospital of Chongqing Medical University, Huaihe Hospital of Henan University, Zhengzhou Cardiovascular Hospital, Wuhan Union Hospital, China, The First Affiliated Hospital of Nanchang University, Hunan Provincial People's Hospital, Tianjin Medical University Second Hospital, First Affiliated Hospital, Sun Yat-Sen University, The First Hospital of Jilin University
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases, Cardiovascular Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
08/25
02/27
NCT06339021: OCT or Angiography Guided De-escalation of DAPT

Not yet recruiting
1
80
RoW
OCT-guided PCI, Conventional angiography-based PCI, DAPT de-escalation, default DAPT regimen
Shenyang Northern Hospital
Optical Coherence Tomography, Dual Antiplatelet Therapy, Antiplatelet De-escalation, Neointimal Coverage, ST Elevation Myocardial Infarction
12/26
12/26
NCT03040934: Firehawk™ Coronary Stent System in the Treatment of Coronary Chronic Total Occlusion Lesion(s)

Active, not recruiting
N/A
196
RoW
Firehawk sirolimus target eluting coronary stent system, Firehawk™, XIENCE Everolimus-Eluting Coronary Stent System, XIENCE EES
Shanghai MicroPort Medical (Group) Co., Ltd.
Drug-Eluting Stents, Percutaneous Coronary Intervention, Tomography, Optical Coherence
09/19
10/23
NCT04569669: The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis

Not yet recruiting
N/A
325
RoW
FFR and FFRCT
CCRF Inc., Beijing, China, Shengshi Technology, Co., Ltd, Hangzhou, China
Coronary Stenosis
10/21
03/22
SIBLINT ISR, NCT04240444: Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis

Completed
N/A
260
RoW
drug-coated balloon Catheter
B. Braun Medical International Trading Company Ltd., CCRF Inc., Beijing, China
Coronary Artery Disease, In Stent Restenosis
07/22
08/22
BEYOND-II, NCT03820622: The Safety and Efficacy of DIOR Balloon in Coronary Bifurcation Lesions

Not yet recruiting
N/A
220
RoW
Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR), Paclitaxel-Eluting Balloon (Bingo)
CCRF Inc., Beijing, China
Percutaneous Coronary Intervention
05/22
10/22
BRIGHT-4, NCT03822975: Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI

Active, not recruiting
N/A
6016
RoW
Bivalirudin, unfractionated Heparin
Shenyang Northern Hospital
ST Elevation Myocardial Infarction
05/22
05/23
NCT05040074: SQ-Kyrin TMVr FIM Study

Recruiting
N/A
20
RoW
SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System
Shanghai Shenqi Medical Technology Co., Ltd
Mitral Regurgitation
10/22
10/26
NCT05375110: NoYA RAISE Trial II (Radiofrequency Ablation-Based Interatrial Shunt for Heart Failure)

Recruiting
N/A
120
RoW
NoYAâ„¢ Radiofrequency Interatrial Shunt System
Hangzhou NOYA MedTech Co. Ltm.
Heart Failure
12/22
12/23
NCT05015712: Effects of MICT on Cardiopulmonary Function in Patients After TAVI

Recruiting
N/A
66
RoW
moderate intensity continuous training
Han Yaling, MD
Valve Disease, Aortic, Cardiac Rehabilitation
06/23
06/23
NCT05988450: Safety and Effectiveness Study of SQ-Kyrin TMVr System for Functional Mitral Regurgitation

Active, not recruiting
N/A
125
RoW
SQ-Kyrin Transcatheter Mitral Valve Repair System
Shanghai Shenqi Medical Technology Co., Ltd
Functional Mitral Regurgitation
12/23
12/27
OPT-GUIDNACE, NCT06216821: OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time

Not yet recruiting
N/A
3490
RoW
standard DAPT, OPT-CAD score guided DAPT de-escalation
Shenyang Northern Hospital
Acute Coronary Syndrome
12/25
12/25
COCAD, NCT06216847: Clinical Outcomes of Patients With Coronary Artery Disease

Not yet recruiting
N/A
10000
RoW
Shenyang Northern Hospital
Coronary Heart Disease (CHD)
10/26
10/30
NCT06357026: Phitys I™ Percutaneous Left Ventricular Assist System Study

Not yet recruiting
N/A
344
RoW
Percutaneous Ventricular Assist System(Phigine Medical), intra-aortic balloon pump (IABP)
Shanghai NewMed Medical Co., Ltd., Shanghai Phigine Medical Technology Co., Ltd.
Coronary Artery Disease
05/25
04/26
NCT05864456: Prizvalve Pro™ Transcatheter Aortic Valve Replacement Study

Recruiting
N/A
73
RoW
Prizvalve Pro™ transcatheter aortic valve system
Shanghai NewMed Medical Co., Ltd., The General Hospital of Northern Theater Command, West China Hospital
Aortic Valve Stenosis
06/24
05/28
NCT06491953: SGLT2-inhibitors on PC-AKI

Recruiting
N/A
3600
RoW
SGLT-2 inhibitors
Shenyang Northern Hospital
Impact of SGLT2-inhibitors on PC-AKI in ACS Patients Receiving Invasive Strategy
12/24
12/24
NCT06101888: Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR)

Recruiting
N/A
116
RoW
TaurusTrio™ Heart Valve System
Peijia Medical Technology (Suzhou) Co., Ltd.
Aortic Regurgitation
07/24
07/29
DragonFire-02, NCT06368037: Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy

Not yet recruiting
N/A
10
RoW
DragonFire Transcatheter Myocardial Radiofrequency Ablation System
Hangzhou Valgen Medtech Co., Ltd
Obstructive Hypertrophic Cardiomyopathy
06/25
06/26
NCT06639321: Phimume® Percutaneous Left Ventricular Assist System Study

Not yet recruiting
N/A
250
RoW
Percutaneous Ventricular Assist System, extracorporeal membrane oxygenation (ECMO)
Shanghai NewMed Medical Co., Ltd., Shanghai Phigine Medical Technology Co., Ltd.
Coronary Artery Disease
11/25
10/26
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus

Recruiting
N/A
184
RoW
Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter
Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Coronary Artery Disease, Intravascular Lithotripsy
12/24
09/25
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System

Not yet recruiting
N/A
2150
RoW
Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy
Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Heart Disease
01/26
01/28
CRUISE-CTO, NCT04944615: To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease.

Recruiting
N/A
1448
RoW
The guidewire successfully passed the CTO lesion, Load dose administration
CCRF Inc., Beijing, China, BSC International Medical Trading (Shanghai) Co., Ltd.
Chronic Total Occlusion of Coronary Artery
10/31
10/31
CHIP-RETENTION, NCT04987268: CHIP and Residual Cardiovascular Event Tendency After Smoking Cessation

Not yet recruiting
N/A
1029
RoW
clonal hematopoiesis of indeterminate potential
Shenyang Northern Hospital
ACS, Clonal Hematopoiesis of Indeterminate Potential, Smoking Cessation
08/23
08/24
Li, Yan
NCT04035824: Gastrodia and Uncaria Recipe in Treating Stage-one Hypertension: an Evidence-based Optimization Study

Completed
4
605
RoW
Gastrodia and Uncaria granule, Placebo of Gastrodia and Uncaria granule
Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hypertension
04/24
04/24
NCT05089448: Morning Versus Bedtime Dosing of Antihypertensive Medication

Recruiting
4
300
RoW
Alisartan, Amlodipine besylate
Yan Li
Hypertension, Blood Pressure, Drug Use
06/26
09/26
NCT03825692: International Clinical Study of Zhizhu Kuanzhong Capsule

Recruiting
4
480
RoW
Zhizhu Kuanzhong Capsule, ZZKZ capsule, Zhizhu Kuanzhong Placebo Capsule, placebo
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Functional Dyspepsia, Postprandial Distress Syndrome
12/23
12/23
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Checkmark Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
Checkmark Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Completed
3
1177
Europe, Canada, Japan, US, RoW
Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC
Eli Lilly and Company
Ulcerative Colitis
11/21
12/24
NCT04078568: Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease

Active, not recruiting
3
3208
RoW
IVIG, Intravenous Immunoglobulins, Human, Aspirin, Acetylsalicylic acid, Prednisolone, STEROLONE
Children's Hospital of Fudan University, Jiangxi Province Children's Hospital, First People's Hospital of Hangzhou, Shengjing Hospital, The First Hospital of Jilin University, Chengdu Women's and Children's Central Hospital, Children's Hospital of Chongqing Medical University, Inner Mongolia People's Hospital, Sichuan Provincial People's Hospital, Wuhan Union Hospital, China, Third Affiliated Hospital of Zhengzhou University, Children's Hospital of Soochow University, Yuying Children's Hospital of Wenzhou Medical University, Beijing Children's Hospital, Qilu Hospital of Shandong University
Kawasaki Disease
12/24
12/25
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Active, not recruiting
3
274
RoW
BPI-16350, placebo, Fulvestrant
Betta Pharmaceuticals Co., Ltd.
Breast Cancer
12/23
07/25
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration

Active, not recruiting
3
488
RoW
TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis
TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Neovascular Age-related Macular Degeneration
09/24
02/25
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
928
Europe, Canada, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Diabetes, Type 2 Diabetes
04/24
04/24
TRAPP, NCT05811676: Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women with Placenta Previa

Recruiting
3
1680
RoW
Tranexamic acid, 0.9% sodium chloride
Guangzhou Medical University, Dongguan Maternal and Child Health Care Hospital, Foshan Women and Children Hospital, BoAi Hospital of Zhongshan, Women and Children's Hospital of Chongqing Medical University, Tianjin Central Hospital of Gynecology Obstetrics, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Urumqi Maternal and Child Health Care Hospital, Zhuhai Women and Children's Hospital, The First Affiliated Hospital of Zhengzhou University, Hunan Provincial Maternal and Child Health Care Hospital, Dalian women and children's medical group, Nanfang Hospital, Southern Medical University, Huadu District People's Hospital of Guangzhou, Northwest Women's and Children's Hospital, Xi'an, Shaanxi, First Affiliated Hospital, Sun Yat-Sen University, Shenzhen Maternity & Child Healthcare Hospital, Shenzhen Baoan Women's and Children's Hospital, Dongguan People's Hospital, First Affiliated Hospital of Xinjiang Medical University, Tongji Hospital, Peking Union Medical College, Peking University First Hospital, The First Affiliated Hospital of Guangzhou Medical University, Second Affiliated Hospital of Guangzhou Medical University, Fifth Affiliated Hospital of Guangzhou Medical University, Shijiazhuang Obstetrics and Gynecology Hospital
Hemorrhage, Postpartum, Placenta Previa
02/25
04/25
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Recruiting
3
218
RoW
ICP-022, Chlorambucil, Rituximab
Beijing InnoCare Pharma Tech Co., Ltd.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/24
06/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT06083623: A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants

Not yet recruiting
2b
2250
RoW
TNM001, placebo
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Respiratory Syncytial Virus Infections
05/26
08/26
NCT04405154: A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer

Not yet recruiting
2
32
NA
Camrelizumab, SHR-1210, Cisplatin, Platinol, IMRT or VMAT
West China Hospital
Head and Neck Neoplasms
05/23
05/25
NCT05299697: A Study of TG103 Injection in Overweight or Obesity

Recruiting
2
195
RoW
TG103 15 mg, TG103 22.5 mg, Placebo
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Overweight or Obesity
06/23
09/23
NCT06206720: A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV

Recruiting
2
60
RoW
Deuremidevir Hydrobromide for Suspension, VV116, Placebo, VV116 placebo
Vigonvita Life Sciences
Respiratory Syncytial Virus Infection
01/25
01/25
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

Not yet recruiting
2
318
RoW
HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes
04/25
04/25
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases

Active, not recruiting
2
103
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627
Novartis Pharmaceuticals
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
07/24
07/26
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
498
Europe, RoW
SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate
Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
12/25
10/26
NCT05879055: A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Recruiting
2
60
RoW
PM8002, FOLFIRI
Biotheus Inc.
Neuroendocrine Neoplasm
01/27
01/28
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Recruiting
1/2
39
RoW
400mg of TQB3909 tablets, 600mg of TQB3909 tablets
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Mantle Cell Lymphoma
12/24
12/24
NCT06052813: A Study of BN104 in the Treatment of Acute Leukemia

Recruiting
1/2
90
RoW
BN104
BioNova Pharmaceuticals (Shanghai) LTD.
ALL, Adult, AML, Adult
06/26
06/27
NCT05056389: Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA)

Recruiting
1
20
Europe
Oxaliplatin, Intraperitoneal catheter
Oslo University Hospital
Peritoneal Metastases, Colo-rectal Cancer
03/23
06/23
NCT05480592: A Study of HS-10380 in Chinese Participants

Recruiting
1
76
RoW
HS-10380, Placebo
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Schizophrenia
06/23
07/23
NCT06594315: Assessing Brain Metabolism Using MRS With Deuterated Glucose

Active, not recruiting
N/A
80
US
Deuterated Glucose, Hydrogen gas (H2) glucose, [6,6'-2H2] glucose, Magnetic Resonance Imaging (MRI), MRI, Blood Sample, MR spectroscopy (MRS), MRS
University of California, San Francisco
Glioma
07/27
07/27
NCT06610604: Health-Related Quality of Life and Emotions in Patients with Thyroid Nodules

Recruiting
N/A
500
RoW
thermal ablation, thyroidectomy
Ming-an Yu
Thyroid Nodule
06/27
12/27
NCT05258461: An Innovative Smartphone Application for Adverse Event Management During Breast Cancer Adjuvant Chemotherapy

Not yet recruiting
N/A
108
NA
use of a smartphone app for adverse event management, conventional adverse event management
Peking Union Medical College Hospital
Breast Cancer
10/22
12/22
NCT03547856: A Registry Study on the "Action of Controlling Ambulatory Blood Pressure to Target in Ten Thousand Patients"

Recruiting
N/A
10000
RoW
Yan Li
Hypertension, Blood Pressure, Cardiovascular Diseases
09/26
12/26
ASORPWICE, NCT03521739: Association of Synchronous Four-limb blOod pRessure and Pulse Wave velocIty With Cardiovascular Events

Recruiting
N/A
100000
RoW
Chinese Academy of Medical Sciences, Fuwai Hospital
Blood Pressure, Pulse Wave Analysis, Ankle Brachial Index, Patient Outcome Assessment
12/22
12/23
CONTROL-NHT, NCT04137549: Registry Study on "Control Nocturnal Hypertension to Reach the Target "

Recruiting
N/A
4500
RoW
Shanghai Institute of Hypertension
Nocturnal Hypertension
09/26
12/26
PROMISE, NCT04135911: A Prospective Study on The"Management of Hypertension in Young and Middle-aged Subjects in Enterprises Setting"

Suspended
N/A
2000
RoW
Yan Li
Hypertension, Blood Pressure
03/26
03/26
NCT05535400: Effects of Physical-Psychological Integrative Intervention on SCI Patient: a Pilot Randomized Controlled Trial

Completed
N/A
72
RoW
Physical-Psychological Integrative Intervention, Brief online didactic education
The Hong Kong Polytechnic University
Spinal Cord Injuries, Physical Inactivity, Depression, Chronic Pain
12/22
07/23
NCT04258787: OCT in Fuchs' Dystrophy

Recruiting
N/A
60
US
Oregon Health and Science University, National Eye Institute (NEI)
Fuchs Dystrophy, Pseudophakic Bullous Keratopathy
06/26
06/26
NCT05558657: Effect of Acupressure on Constipation in Community-dwelling Spinal Cord Injury Patients: a Randomized Controlled Trial

Completed
N/A
80
RoW
Home-based, acupressure combined with nursing education, Home-based, manual light touch of the abdomen combined with nursing education
The Hong Kong Polytechnic University
Spinal Cord Injuries, Traditional Chinese Medicine
09/24
09/24
NCT05531058: The Impact of a Web-based Psychoeducation Programme With a Motivational AI Chatbot on Covid-19 Vaccine Hesitancy

Completed
N/A
168
RoW
AI-driven Vaccine Communicator, Self-learning of COVID-19 vaccine knowledge
The Hong Kong Polytechnic University
Vaccine Hesitancy, COVID-19
06/24
06/24
NCT01243931: Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

Recruiting
N/A
80
US
OCT-guided laser phototherapeutic keratectomy, Manufacturer/Name OCT Technology 510(K), Optovue/RTVue-CAM Fourier-domain K071250, Bioptigen/Bioptigen Fourier-domain K063343, Zeiss/Visante Time-domain K051789
Oregon Health and Science University, National Eye Institute (NEI)
Corneal Opacity
12/26
12/26
NCT02109471: Observational Study of Corneal Opacities in Adults

Recruiting
N/A
150
US
Oregon Health and Science University, National Eye Institute (NEI)
Corneal Opacities (Scar and Stromal Dystrophy)
12/25
12/25
NCT02026128: Optical Coherence Tomography (OCT) in Uveitis

Recruiting
N/A
75
US
Oregon Health and Science University
Uveitis
12/25
12/25
NCT06306378: The Relationship Between Social Memory Disorders and Sleep Spindles in Children With Autism Spectrum Disorder

Recruiting
N/A
60
RoW
social memory levels and spindle levels
First Affiliated Hospital Xi'an Jiaotong University, Xi'an TCM Hospital of Encephalopathy
Autism Spectrum Disorder
03/24
04/24
NCT03504800: OCT in Diagnosis of Irregular Corneas

Recruiting
N/A
445
US
Optical Coherence Tomography
Oregon Health and Science University
Keratoconus, Corneal Opacity, Corneal Dystrophy
04/25
04/26
NCT05388110: SKY Breath Intervention

Active, not recruiting
N/A
60
US
SKY Breath Intervention
University of California, San Francisco
Depression, Anxiety Disorders
04/25
12/25
OCT IOL, NCT00532051: Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography

Recruiting
N/A
690
US
OCT measurements, Manufacturer/Name OCT Technology 510(K), Optovue/RTVue-CAM Fourier-domain K071250, Bioptigen/Bioptigen Fourier-domain K063343, Zeiss/Visante Time-domain K051789
Oregon Health and Science University, National Eye Institute (NEI)
Cataract
07/26
07/26
NCT06686134: Comprehensive Clinical Evaluation Study of GLP-1RA

Recruiting
N/A
492
RoW
LI YAN
T2DM
12/25
07/26
INFINITE, NCT04328662: A Study of Ninlaro in Real World Clinical Practice in China

Active, not recruiting
N/A
482
RoW
Takeda
Multiple Myeloma, Neoplasms, Plasma Cell
09/25
09/25
TEAS/ASD, NCT06763237: Abdominal Transcutaneous Electrical Acupoint Stimulation on Children With Autism Spectrum Disorder

Not yet recruiting
N/A
42
RoW
abdominal transcutaneous electrical acupoint stimulation (abdominal TEAS), TEAS, Applied Behavior Analysis (ABA) therapy
First Affiliated Hospital Xi'an Jiaotong University, Xian Children's Hospital
Autism Spectrum Disorder, Autism in Children
01/26
01/26
NCT06839378: Flura-seq for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei

Recruiting
N/A
36
RoW
intravenously inject with 5-FU (400 mg/m2)
Beijing Tsinghua Chang Gung Hospital, Tsinghua University
Pseudomyxoma Peritonei
02/26
02/27
NCT05282095: Effect of HPV Integration on Prognosis of Young Women With CIN2 in China

Recruiting
N/A
300
RoW
Follow up
Fujian Maternity and Child Health Hospital
Cervical Intraepithelial Neoplasia, HPV Infection, Virus Integration, HSIL, High Grade Squamous Intraepithelial Lesions
12/25
05/26
NCT05881967: Molecular Mechanism Study of Uterine Sarcoma

Recruiting
N/A
300
RoW
Diagnostic biomarker
Shixuan Wang
Uterine Sarcoma
11/25
11/25
NCT04570020: Scleral Lens Fitting Using Wide-Field OCT

Recruiting
N/A
258
US
Oregon Health and Science University, National Eye Institute (NEI)
Keratoconus, Irregular; Contour of Cornea
12/25
12/26
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System

Not yet recruiting
N/A
2150
RoW
Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy
Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Heart Disease
01/26
01/28
SHAFT, NCT04574336: Scandinavian Humeral Diaphyseal Fracture Trial

Recruiting
N/A
287
Europe
Surgical treatment, Non-surgical treatment
Kolding Sygehus, Copenhagen University Hospital, Hvidovre, Zealand University Hospital, Oslo University Hospital, Helse Stavanger HF, Sahlgrenska University Hospital, Sweden, Uppsala University Hospital, Odense University Hospital, Hospital of Southern Jutland, Slagelse Hospital, Aalborg University Hospital, University Hospital, Umeå, Nordsjaellands Hospital, Holbaek Sygehus, Aarhus University Hospital, Copenhagen University Hospital, Herlev-Gentofte, University Hospital Bispebjerg and Frederiksberg, Viborg Regional Hospital, Karolinska University Hospital, Danderyd Hospital, Tampere University Hospital, Helsinki University Central Hospital
Fracture Humerus of Shaft
12/25
07/31
NCT05858944: Home Blood Pressure Intervention in the Community Trial

Recruiting
N/A
10000
RoW
Intensive Home BP control, Home BP<125/75 mmHg, Standard Home BP control, Home BP<135/85 mmHg
Shanghai Institute of Hypertension
Home Blood Pressure
12/29
06/30
MBS, NCT05205187: Gut Microbiota and Metabonomics

Recruiting
N/A
450
RoW
Healthy control specimen collection, Non-Borrmann IV patient specimen collection, Borrmann IV patient specimen collection
First Hospital of China Medical University, Liaoning Cancer Hospital & Institute, The Second Hospital of Shandong University, The General Hospital of Fushun Mining Bureau, The fourth People's Hospital of Changzhou, The First People's Hospital of Jingzhou
Stomach Neoplasms, Gut Microbiota, Metabolomics
01/24
12/25
LORMYF, NCT05424393: Real-World Study on Long-term Treatment With YISAIPU for Fujian RA Patients

Recruiting
N/A
500
RoW
YISAIPU® ( An etanercept biosimilar), a recombinant tumor necrosis factor receptor-Fc fusion protein, rhTNFR:Fc, csDMARDs
The First Affiliated Hospital of Xiamen University
Rheumatoid Arthritis
06/25
12/25
Fan, Jia
NCT05660213: Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC)

Not yet recruiting
4
600
NA
Huaier granule, Atezolizumab + Bevacizumab, Camrelizumab+Apatinib, Sintilimab+Bevacizumab
Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology
Unresectable Hepatocellular Carcinoma
09/25
01/27
NCT04720716: A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Recruiting
3
490
RoW
IBI310, Sintilimab, Sorafenib
Innovent Biologics (Suzhou) Co. Ltd.
Hepatocellular Carcinoma
12/23
12/23
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Active, not recruiting
3
648
RoW
AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Hepatocellular Carcinoma (HCC)
12/26
12/26
NCT05320692: A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

Recruiting
3
425
RoW
TACE+Camrelizumab+Apatinib mesylate, TACE
Jiangsu HengRui Medicine Co., Ltd.
Hepatocellular Carcinoma
07/26
07/26
EMERALD-2, NCT03847428 / 2018-004105-85: Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

Hourglass Jan 2022 - Dec 2023 : Acceptance of regulatory submission in China for HCC based on EMERALD-2 trial
Jan 2023 - Jun 2023: Data from EMERALD-2 trial for HCC
Active, not recruiting
3
908
Europe, Canada, Japan, US, RoW
Durvalumab, IMFINZI, Bevacizumab, AVASTIN, Placebo
AstraZeneca, AstraZeneca AB
Hepatocellular Carcinoma
05/26
05/27
AK104-306, NCT05489289: A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Not yet recruiting
3
405
RoW
AK104, placebo
Akeso
Hepatocellular Carcinoma
01/25
11/26
NCT04669496: Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors

Recruiting
2/3
178
RoW
Neoadjuvant treatment
Shanghai Zhongshan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 6th People's Hospital, Shanghai Public Health Clinical Center, RenJi Hospital, Shenzhen University General Hospital
Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy
12/25
12/26
DUBHE-H-308, NCT05976568: A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Not yet recruiting
2/3
668
RoW
QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine, Sintilimab
Qilu Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
09/27
09/27
NCT04506281: PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Recruiting
2
128
RoW
neoadjuvant treatment
Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Minhang Hospital, Fudan University, Shanghai Jinshan Hospital, Shenzhen University General Hospital
Cholangiocarcinoma, Intrahepatic
08/21
08/23
ZSAB-TOP, NCT05023109: GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC

Active, not recruiting
2
45
RoW
GP+PD-1+Tight
Shanghai Zhongshan Hospital, Jining Medical University, Cancer Hospital of Guangxi Medical University
Biliary Tract Carcinoma
01/23
12/24
NCT05190575: TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer

Completed
2
8
RoW
TST001
Shanghai Zhongshan Hospital, Transcenta Holding Limited
Biliary Tract Neoplasms
05/23
05/23
ZSAB-TransGOLP, NCT05156788: Tislelizumab(Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Active, not recruiting
2
40
RoW
PD-1+Lenvatinib+GEMOX
Shanghai Zhongshan Hospital
Biliary Tract Cancer, PD-1 Antibody, Gemox, Lenvatinib
07/23
10/25
NCT04550624: Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma

Recruiting
2
40
RoW
Pembrolizumab Injection [Keytruda], Keytruda, Lenvatinib Mesylate, Lenvima
Shanghai Jiahui International Hospital, Shanghai Zhongshan Hospital
Advanced Biliary Tract Carcinoma
12/24
12/25
SHR-A1811-212, NCT06413745: Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

Recruiting
2
65
RoW
SHR-A1811
Jiangsu HengRui Medicine Co., Ltd.
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
09/25
09/25
NCT06349980: A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

Recruiting
2
117
RoW
HLX53 (1000mg), HLX53 (2000mg), HLX10, Serplulimab, HLX04, Bevacizumab, Placebo
Shanghai Henlius Biotech
Carcinoma, Hepatocellular
02/27
02/27
NCT06620848: A Study of HRS-4642 Monotherapy or in Combination with Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.

Not yet recruiting
2
49
RoW
HRS-4642 monotherapy, HRS-4642 and adebrelimab combination therapy
Shanghai Zhongshan Hospital
Biliary Tract Cancer
12/26
06/27
FAITH, NCT06031480: Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors

Not yet recruiting
2
55
RoW
Anlotinib and TQB2450
Shanghai Zhongshan Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatocellular Carcinoma
10/25
12/25
NCT03867370: Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Terminated
1/2
40
RoW
Toripalimab (JS001 ), Toripalimab (JS001 ) Lenvatinib
Shanghai Junshi Bioscience Co., Ltd.
Hepatocellular Carcinoma
08/23
08/23
 

Download Options